Profiling the immune landscape in mucinous ovarian carcinoma

NS Meagher; P Hamilton; K Milne; S Thornton; B Harris; A Weir; J Alsop; C Bisinoto; JD Brenton; A Brooks-Wilson; DS Chiu; KL Cushing-Haugen; S Fereday; DW Garsed; SA Gayther; A Gentry-Maharaj; B Gilks; M Jimenez-Linan; CJ Kennedy; ND Le; AM Piskorz; MJ Riggan; M Shah; N Singh; A Talhouk; M Widschwendter; DDL Bowtell; FJ Candido dos Reis; LS Cook; RT Fortner; MJ García; HR Harris; DG Huntsman; AN Karnezis; M Köbel; U Menon; PDP Pharoah; JA Doherty; MS Anglesio; MC Pike; CL Pearce; ML Friedlander; A DeFazio; BH Nelson; SJ Ramus

Journal article

Profiling the immune landscape in mucinous ovarian carcinoma

NS Meagher, P Hamilton, K Milne, S Thornton, B Harris, A Weir, J Alsop, C Bisinoto, JD Brenton, A Brooks-Wilson, DS Chiu, KL Cushing-Haugen, S Fereday, DW Garsed, SA Gayther, A Gentry-Maharaj, B Gilks, M Jimenez-Linan, CJ Kennedy, ND Le Show all

Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2023

DOI: 10.1016/j.ygyno.2022.10.022

Abstract

Objective: Mucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer, with low response rates to standard chemotherapy, and very poor survival for patients diagnosed at advanced stage. There is a limited understanding of the MOC immune landscape, and consequently whether immune checkpoint inhibitors could be considered for a subset of patients. Methods: We performed multicolor immunohistochemistry (IHC) and immunofluorescence (IF) on tissue microarrays in a cohort of 126 MOC patients. Cell densities were calculated in the epithelial and stromal components for tumor-associated macrophages (CD68+/PD-L1+, CD68+/PD-L1-), T cells (CD3+/CD8-, CD3+/CD8+), putative T-regulatory cells (T..

View full abstract

University of Melbourne Researchers

Julie Fereday Author

Dale Garsed Author

David Bowtell Author

Related Projects (8)

Australian Biospecimen Network-Oncology

Availability of ethically consented, clinically annotated human cancer tissue is a key determinant of the international competitiveness of A..

Molecular Epidemiology of Ovarian Research Institute

PUBLIC ABSTRACT A major obstacle to preventive strategies for ovarian cancer is the lack of recognized modifiable risk factors. Age, a pos..

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

AUSTRALASIAN BIOSPECIMEN NETWORK-ONCOLOGY

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

IMPROVING OUTCOMES FOR WOMEN WITH EPITHELIAL OVARIAN CANCER

THE MOLECULAR BIOLOGY OF HUMAN OVARIAN CANCER

The Fellowship would support Professor Bowtell, one of the world’s leading ovarian cancer researchers. His work focuses on clinical problems..

UNDERSTANDING ADVERSE AND EXCEPTIONAL OUTCOMES IN OVARIAN CANCER

Most women with high-grade serous ovarian cancer (HGSC) die within five years of diagnosis, as tumours often develop chemotherapy resistance..

Grants

Awarded by Cancer Council Victoria

Funding Acknowledgements

Funding This work was supported by the U.S. Army Medical Research and Materiel Command through the Ovarian Cancer Research Program under Award No. W81XWH-16-2-0010. We are grateful for financial support for this study from UNSW Faculty of Medicine and Health. Funding for this study came from the accelerator grant of NSW Health PhD Scholarship Program awarded to Nicola S Meagher.